Phase 1/2 Trial Set to Test ASC618, Gene Therapy for Hemophilia A
The U.S. Food and Drug Administration (FDA) has approved ASC Therapeutics’...
Read MoreASC Therapeutics Receives IND Clearance From the U.S. Food and Drug Administration for ASC618 Second-Generation Gene Therapy for Hemophilia A
BusinessWire Transformational in-vivo AAV gene therapy for hemophilia A Efficiently...
Read More
ASC Therapeutics “Advanced Genome Editing, Gene & Cell Therapy Platforms in the US and China” won the first prize
ASC Therapeutics “Advanced Genome Editing, Gene & Cell Therapy Platforms...
Read More
Clinical Development of Advanced Gene Therapies for Hemophilia.
https://www.youtube.com/watch?v=yicEn7XZ-W8&feature=youtu.be
Read More
ASC Therapeutics and Vigene Announce Long-Term Strategic Partnership for Gene Therapy Development and Manufacturing
MILPITAS, Calif.–(BUSINESS WIRE)–ASC Therapeutics (“ASC”), a privately-held gene therapy company...
Read More
ASC Therapeutics Licenses Tech from Expression Therapeutics to Advance Gene Therapies
5/16/19 MILPITAS, Calif.–(BUSINESS WIRE) — ASC Therapeutics, A Division of Applied...
Read More
ASC Therapeutics Cures Hemophilia A Mice
4/25/19 MILPITAS, Calif.–(BUSINESS WIRE)– Applied StemCell, Inc. (ASC), a leading gene-editing company,...
Read More